Search - tctmd.com

Displaying 121 - 140 of 242

Sort: Relevancy | Date

Presentation TCT 2017

TCT 75: Impact of the Timing of P2Y12 Inhibitor Discontinuation Prior to CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Presenter: Adrian P. Banning, John D. Puskas, Christopher Kelly, MD

October 31, 2017

Presentation TCT 2017

The Global Vision of Cardiovascular Regenerative Medicine: The TACTICS Alliance

Presenter: Anthony N. DeMaria, Francisco Fdez-Aviles

October 30, 2017

Presentation TCT 2017

In This Case: Doppler-Based CFR Uncovered Discordance With FFR (With Discussion)

Presenter: Justin E. Davies, Nils Johnson, Tim P. van de Hoef

October 30, 2017

Presentation TCT 2017

The American Vision of Regenerative Cardiovascular Medicine

Presenter: Anthony N. DeMaria, Francisco Fdez-Aviles

October 30, 2017

Presentation TCT 2017

The European Vision of Regenerative Cardiovascular Medicine: The New CARE Working Group of the ESC

Presenter: Anthony N. DeMaria, Francisco Fdez-Aviles, Jens Kastrup

October 30, 2017

Presentation TCT 2016

Identifying and Treating Benign Discontinuities From More Meaningful Intraluminal Scaffold Dismantling and Fractures (With Case Examples)

Presenter: Ashok Seth, Pieter C. Smits, Yoshinobu Onuma

November 01, 2016

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

Improving Clinical Science: Priorities and Methods of Clinical Trials in Cardiovascular Regenerative Medicine

Presenter: Emerson C. Perin, Bernard J. Gersh

October 31, 2016

Presentation TCT 2016

Cells at the Moment of Truth: Findings From Meta-analysis and Systematic Reviews

Presenter: Emerson C. Perin, Mariann Gyöngyösi

October 31, 2016

Presentation TCT 2016

Beyond Cells: Cardiac Gene Therapy In Perspective

Presenter: Emerson C. Perin, Marc S. Penn

October 31, 2016

Presentation TCT 2016

New Sights from CHART -1 at 1 Year: Relationship of outcomes to baseline biomarkers and treatment intensity

Presenter: Emerson C. Perin, Jozef Bartunek

October 31, 2016

Presentation TCT 2016

Cells Alone Work: Lessons From Recent Clinical Trials

Presenter: Emerson C. Perin

October 31, 2016

Presentation TCT 2016

When Everything Has Disappeared: Role of Cell-Based Engineered Tissue and Organ Transplantation.

Presenter: Timothy D. Henry, Amit N. Patel, Doris A. Taylor

October 31, 2016

Presentation TCT 2016

When Cells are Not Enough: Role of Cellular and Non-Cellular Injectable Biomaterials

Presenter: Timothy D. Henry, Amit N. Patel

October 31, 2016

Presentation TCT 2016

Site-reported vs Core Lab Syntax Scores: Discordance and Impact on Outcomes After PCI vs CABG in EXCEL

Presenter: A. Pieter Kappetein, Marie-Claude Morice, Philippe Généreux

October 31, 2016

Presentation TCT 2016

Improving Translational Science In Cardiac Regenerative Medicine. Utility of Animal Models

Presenter: Timothy D. Henry, Amit N. Patel, Steven A.J. Chamuleau

October 31, 2016

Presentation TCT 2016

Obstacles for Clinical Research: Perspectives From Industry

Presenter: Emerson C. Perin, Ricardo Sanz-Ruiz, Warren Sherman

October 31, 2016

Presentation TCT 2016

Obstacles for Clinical Research: The BAMI Experience

Presenter: Emerson C. Perin, Ricardo Sanz-Ruiz

October 31, 2016

Presentation TCT 2016

Regenerative Products In Perspective: Do They Really Work? Are They Enough?

Presenter: Emerson C. Perin, Ricardo Sanz-Ruiz, Jens Kastrup

October 31, 2016

Presentation TCT 2016

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Presenter: Mitchell W. Krucoff, Shigeru Saito, Christopher B. Granger

October 30, 2016

Advertisement

TCT 75: Impact of the Timing of P2Y12 Inhibitor Discontinuation Prior to CABG in Patients With Left Main Disease: Results from the EXCEL Trial

The Global Vision of Cardiovascular Regenerative Medicine: The TACTICS Alliance

In This Case: Doppler-Based CFR Uncovered Discordance With FFR (With Discussion)

The American Vision of Regenerative Cardiovascular Medicine

The European Vision of Regenerative Cardiovascular Medicine: The New CARE Working Group of the ESC

Identifying and Treating Benign Discontinuities From More Meaningful Intraluminal Scaffold Dismantling and Fractures (With Case Examples)

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Improving Clinical Science: Priorities and Methods of Clinical Trials in Cardiovascular Regenerative Medicine

Cells at the Moment of Truth: Findings From Meta-analysis and Systematic Reviews

Beyond Cells: Cardiac Gene Therapy In Perspective

New Sights from CHART -1 at 1 Year: Relationship of outcomes to baseline biomarkers and treatment intensity

Cells Alone Work: Lessons From Recent Clinical Trials

When Everything Has Disappeared: Role of Cell-Based Engineered Tissue and Organ Transplantation.

When Cells are Not Enough: Role of Cellular and Non-Cellular Injectable Biomaterials

Site-reported vs Core Lab Syntax Scores: Discordance and Impact on Outcomes After PCI vs CABG in EXCEL

Improving Translational Science In Cardiac Regenerative Medicine. Utility of Animal Models

Obstacles for Clinical Research: Perspectives From Industry

Obstacles for Clinical Research: The BAMI Experience

Regenerative Products In Perspective: Do They Really Work? Are They Enough?

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content